EUVIMEDEUVIMED entdecken
Übersichtsarbeit

Advancing Perioperative Treatment Options for Localized Muscle-Invasive Bladder Cancer: A Step Forward

Maria J Ribal, Jonathan Rosenberg, Tarek Ajami, Antoni Vilaseca, Leilei Xia, Michal Sternschuss, Anne K Schuckman

American Society of Clinical Oncology Educational Book · 2025-06 · 45 (3)

DOI: 10.1200/edbk-25-472822 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift American Society of Clinical Oncology Educational Book, 2025-06. Verfasst von Maria J Ribal und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Urology, Hospital Clínic de Barcelona, Barcelona, Spain. Hauptthemen laut MEDLINE: Urinary Bladder Neoplasms, Perioperative Care. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 60 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Muscle-invasive bladder cancer (MIBC) is an aggressive disease, with substantial recurrence risk after radical cystectomy and pelvic lymph node dissection alone. In cisplatin-eligible patients, administration of neoadjuvant cisplatin-based chemotherapy followed by radical cystectomy has been shown to improve overall survival (OS) and has become the standard of care. Nevertheless, approximately 40%-50% of patients will still experience disease recurrence after curative-intent treatment. Moreover, a significant proportion of patients with MIBC are ineligible for cisplatin and represent a challenging clinical scenario. In recent years, different strategies aiming to improve patient outcomes by incorporating immune checkpoint inhibitors in the treatment paradigm were explored. Two key management approaches emerged: neoadjuvant chemotherapy with risk-adapted adjuvant immunotherapy and universal perioperative immunotherapy-based treatment. We review the rationale, current evidence, challenges, and future directions for the perioperative management of muscle-invasive urothelial carcinoma.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Urinary Bladder NeoplasmsPerioperative CareHumansNeoplasm InvasivenessNeoadjuvant TherapyCystectomyCombined Modality Therapy

Autor:innen und Institutionen

  • Department of Urology, Hospital Clínic de Barcelona, Barcelona, Spain.
  • Memorial Sloan Kettering Cancer Center, New York, NY.
  • Department of Urology, University of Southern California Norris Comprehensive Cancer Center, Los Angeles, CA.

Zitieren

APA

Ribal, M. J., Rosenberg, J., Ajami, T., Vilaseca, A., Xia, L., Sternschuss, M., & Schuckman, A. K. (2025). Advancing Perioperative Treatment Options for Localized Muscle-Invasive Bladder Cancer: A Step Forward. American Society of Clinical Oncology Educational Book, 45(3). https://doi.org/10.1200/edbk-25-472822

Vancouver

Ribal MJ, Rosenberg J, Ajami T, Vilaseca A, Xia L, Sternschuss M, et al. Advancing Perioperative Treatment Options for Localized Muscle-Invasive Bladder Cancer: A Step Forward. American Society of Clinical Oncology Educational Book. 2025;45(3). doi:10.1200/edbk-25-472822

BibTeX
@article{Ribal2025,
  author = {Ribal, Maria J and Rosenberg, Jonathan and Ajami, Tarek and Vilaseca, Antoni and Xia, Leilei and Sternschuss, Michal and Schuckman, Anne K},
  title = {Advancing Perioperative Treatment Options for Localized Muscle-Invasive Bladder Cancer: A Step Forward},
  journal = {American Society of Clinical Oncology Educational Book},
  year = {2025},
  volume = {45},
  number = {3},
  doi = {10.1200/edbk-25-472822}
}
Kostenlos starten →